Smart Clot

Project "Smart Clot" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Today there is a big concern about cardiovascular diseases (CVD); because each year, it causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. With almost 49 million people living with cardiovascular disease in the EU, these problems have a huge impact on public health and on health and economic resources, with a total cost of € 2.10 billion/year. Unfortunately, over the last 25 years the number of cardiovascular diseases cases has increased in Europe. The current medical devices monitor just platelet aggregation or coagulation providing inaccurate estimations and in consequence observing insufficient therapy in thrombosis treatment or excessive therapy dosage in bleeding cases in individual patients. In response, we at SEDICIDODICI have developed, SMART CLOT, a cutting-edge technology for the combined evaluation of coagulation and platelet function for monitoring i) haemostasis (process which causes bleeding to stop, keeping the blood within a damaged blood vessel) as diagnosis tool and ii) antithrombotic treatment to control patients with diseases such as cardiovascular diseases, hypertension, thrombosis, diabetes, pulmonary embolism. It is a user-friendly, automated and real-time platform that provides qualitative/quantitative information based on an instrument and an array of multifunctional flow cartridges designed to interrogate specific pathways of both coagulation and platelet activation under relevant arterial and venous flow conditions. Before reaching market maturity we need in Phase 1 to run a Feasibility Study that helps us organise technical, commercial and financial plan of the project. Finally, SMART CLOT will bring an effective platform for the diagnosis and antithrombotic treatment. SEDICIDODICI will concentrate on the growth of SMART CLOT and in 5 years from launch we expect to earn € 22.3 million in profits, 24 new people and a ROI of 6.08 per euro invested.